US EditionPublished • loading... • Updated
Merck and Calla Lily Partner to Advance Callavid Platform
Summary by Verdict Hospital
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Calla Lily Clinical Care and Merck announce collab to advance drug delivery platform
Calla Lily Clinical Care, a women’s health-focused medtech company, and Merck, a science and technology company, have entered a strategic collaboration to support the continued development of Callavid, a platform for intravaginal drug delivery.
Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
Enhancing patient treatment experience and care with a new self-administered solution for vaginal therapeutics Versatile platform technology developed from a safe, award-winning, FDA-cleared medical device Strategic collaboration supporting the continued development of a novel intravaginal drug delivery approach to address unmet needs in women’s health LONDON--(BUSINESS WIRE)--Calla Lily Clinical Care, a women’s health-focused medical technology…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
